Can Antiphospholipid Syndrome Cause Cardiomyopathy?
Yes, antiphospholipid syndrome (APS) can cause cardiomyopathy, most commonly presenting as dilated cardiomyopathy secondary to myocardial thrombotic microangiopathy, though this is a rare manifestation of the disease.
Mechanism and Pathophysiology
APS causes cardiomyopathy through thrombotic microangiopathy affecting the myocardium 1, 2. The antiphospholipid antibodies—particularly anti-β2-glycoprotein I antibodies—promote endothelial dysfunction, tissue factor expression, platelet activation, complement amplification, and neutrophil extracellular trap formation 2. This immunothrombotic process leads to microvascular ischemic injury within the myocardium, resulting in ventricular dysfunction.
Clinical Presentations
APS-related cardiomyopathy typically manifests as:
- Dilated cardiomyopathy (most commonly reported) 3, 1, 4, 5
- Hypertrophic non-obstructive cardiomyopathy (rare variant) 6
- Biventricular dysfunction with potential progression to cardiogenic shock 7
The dilated form results from widespread myocardial thrombotic microangiopathy causing transmural necrosis and subsequent ventricular dilation 7.
Diagnostic Considerations
When evaluating suspected APS-related cardiomyopathy, look for:
- Intracardiac thrombi on echocardiography (frequently present) 4
- Markedly elevated anticardiolipin antibodies 4
- Triple positivity (lupus anticoagulant + anticardiolipin + anti-β2GPI antibodies), which indicates highest risk 8, 9
- Extracardiac thrombotic manifestations (brain, renal, iliac veins), though cardiomyopathy can be the sole manifestation 1
Prognosis and Management Implications
APS-associated cardiomyopathy confers a poor prognosis 7. The condition can be:
- Resistant to standard heart failure therapy 4
- Rapidly progressive to multiorgan failure 4
- Potentially catastrophic when presenting as cardiogenic shock 7
However, early recognition and adequate anticoagulation with steroids can prevent clinical worsening 1, 5. Some patients respond well to this combination therapy 5.
Treatment Approach
For APS-related cardiomyopathy:
- Immediate anticoagulation with vitamin K antagonists (VKAs remain the cornerstone) 2, 10
- Corticosteroids for the inflammatory component 1, 5
- Plasmapheresis in catastrophic presentations 7
- Advanced therapies: mechanical circulatory support (ECMO) or heart transplantation may be necessary in refractory cases 7
Critical Pitfalls
- Do not use DOACs in high-risk APS (triple positive or arterial thrombosis), as randomized trials show excess recurrent thrombosis, especially arterial events 2, 10
- Recognize that cardiomyopathy may be the only manifestation of APS without other systemic thrombotic features 1
- Maintain vigilance during perioperative periods when anticoagulation is altered, as thrombosis risk peaks during warfarin withdrawal or before adequate anticoagulation is achieved 3
- Consider APS in young patients with unexplained dilated cardiomyopathy, particularly those with intracardiac thrombi 4
The 2023 ACR/EULAR classification criteria now incorporate cardiovascular manifestations including valvular and microvascular domains 2, 11, reflecting growing recognition of cardiac involvement in APS.